Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of TAK-925 to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of TAK-925 in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy

NCT03332784 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03332784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03332784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of TAK-925 to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of TAK-925 in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Completed
Start date
November 4, 2017
Completion date
September 4, 2018
Enrollment
58 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants and patients with narcolepsy